



or a stereoisomeric form of the compound of formula I, or a physiologically tolerated salt of the compound of formula I; and

a third component comprising a pharmaceutically tolerated excipient;

wherein the first component has a concentration from about 2 to about 20 mg and the second component has a concentration from about 0.3% to about 50% of the first component.

REMARKS

Claims 12-29 are currently pending. Claims 12, 20, 26, and 27 have been amended to correct the printing error that occurred in the structural formula of formula I. Specifically, the cyano group that is alpha to the carbonyl moiety did not print correctly in the July 15, 1998 preliminary amendment. Support for this amendment can be found

B3 200005 202-408-4000

LAW OFFICES

FINNEGAN, HENDERSON,
FARABOW, GARRETT
& DUNNER, L.L.P.
1300 I STREET, N.W.
WASHINGTON, D. C. 20005
202-408-4000

